No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GKOS240816P95000
- 1.25
- -0.50-28.57%
15min DelayTrading Jul 23 09:30 ET
1.25High1.25Low
1.25Open1.75Pre Close1 Volume13 Open Interest95.00Strike Price125.00Turnover87.05%IV25.10%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry1.25Extrinsic Value100Contract SizeAmericanOptions Type-0.0871Delta0.0056Gamma100.14Leverage Ratio-0.0893Theta-0.0075Rho-8.72Eff Leverage0.0515Vega
Intraday
- 5D
- Daily
News
Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?
Glaukos Price Target Raised to $141.00/Share From $125.00 by Truist Securities
Glaukos Is Maintained at Buy by Truist Securities
Truist Financial Initiates Glaukos(GKOS.US) With Buy Rating, Announces Target Price $141
Express News | Glaukos Corp : Truist Securities Raises Target Price to $141 From $125
Truist Raises Price Target on Glaukos to $141 From $125, Maintains Buy Rating
Comments
Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.
Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%
Last week’s PDUFAs:
$Arcutis Biotherapeutics(ARQT.US$ :![]()
Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co(MRK.US$ : Approved 12/15![]()
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos(GKOS.US$ : Approved 12/14![]()
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co(MRK.US$ : Approved ...
$Arcutis Biotherapeutics(ARQT.US$ :
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co(MRK.US$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos(GKOS.US$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co(MRK.US$ : Approved ...
7
1
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics(CRSP.US$ $Vertex Pharmaceuticals(VRTX.US$ $OptiNose(OPTN.US$ $Arcutis Biotherapeutics(ARQT.US$ $Calliditas Therapeutics(CALT.US$ $bluebird bio(BLUE.US$ $Glaukos(GKOS.US$ $Ionis Pharmaceuticals(IONS.US$ $Amgen(AMGN.US$ $Merck & Co(MRK.US$
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics(CRSP.US$ $Vertex Pharmaceuticals(VRTX.US$ $OptiNose(OPTN.US$ $Arcutis Biotherapeutics(ARQT.US$ $Calliditas Therapeutics(CALT.US$ $bluebird bio(BLUE.US$ $Glaukos(GKOS.US$ $Ionis Pharmaceuticals(IONS.US$ $Amgen(AMGN.US$ $Merck & Co(MRK.US$
7
2
Glaukos' stock carries risk due to losses and high debt, despite cash reserves. The absence of EBIT level profits and free cash flow make sustainability questionable. Investors should proceed with caution.
Read more